GlycoVaxyn

edit

GlycoVaxyn has built a broad portfolio of conjugate vaccines against common severe bacterial infections based on its unique, proprietary invivo glycosylation platform. With this platform, the company can develop and produce immunogenic glycoproteins in a simplified biological process that circumvents many of the difficulties involved in current methods. The lead conjugate vaccines in development are directed against Shigella dysenteriae, to prevent serious intestinal infections, and against hospital acquired Staphylococcus aureus. GlycoVaxyn also has active programs against N. meningitidis and Group A Streptococcus. GlycoVaxyn, a spinout of the Swiss Federal Institute of Technology (ETH), is based in Schlieren, near Zurich, Switzerland.

Milestones

edit

• Received $21.3M in Series B funding. (3/5/09)
  Posted 6/19/09 at 6:12am

Videos

Screenshots

edit

Sources

1. GlycoVaxyn AG Raises CHF 25 Million in Financing Led by Edmond de Rothschild Investment Partners (bio-medicine.org) [edit]